| Arlaine B Gutierrez, MD | |
|
1144 Coffee Rd, Modesto, CA 95355-4205 | |
| (209) 550-4744 | |
| Not Available |
| Full Name | Arlaine B Gutierrez |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1144 Coffee Rd, Modesto, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245298884 | NPI | - | NPPES |
| 00A637540 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | A63754 (California) | Primary |
| Entity Name | Sutter Valley Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669846986 PECOS PAC ID: 9830094515 Enrollment ID: O20090311000335 |
News Archive
Neurodegenerative diseases represent one of the greatest challenges of our aging society. However, investigation into these diseases is made particularly difficult due to the limited availability of human brain tissue. Scientists from the Life & Brain Research Center and Neurology Clinic of Bonn University have now taken a roundabout path: They reprogrammed skin cells from patients with a hereditary movement disorder into so-called induced pluripotent stem cells (iPS cells) and obtained functional nerve cells from them.
An international team of scientists led by a Cold Spring Harbor Laboratory (CSHL) investigator has discovered that the deadly facial tumors decimating Australia's Tasmanian devil population probably originated in Schwann cells, a type of tissue that cushions and protects nerve fibers.
A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Medication poisonings among children are an important public health problem. During 2010-2011, an average of 1500 children under 6 years of age was evaluated in emergency departments each year due to unintentional exposure to buprenorphine. Ingestion of strong opioids, such as buprenorphine, can cause central nervous system depression, respiratory depression, and death in young children.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arlaine B Gutierrez, MD 600 Coffee Rd, Modesto, CA 95355-4201 Ph: (209) 524-1211 | Arlaine B Gutierrez, MD 1144 Coffee Rd, Modesto, CA 95355-4205 Ph: (209) 550-4744 |
News Archive
Neurodegenerative diseases represent one of the greatest challenges of our aging society. However, investigation into these diseases is made particularly difficult due to the limited availability of human brain tissue. Scientists from the Life & Brain Research Center and Neurology Clinic of Bonn University have now taken a roundabout path: They reprogrammed skin cells from patients with a hereditary movement disorder into so-called induced pluripotent stem cells (iPS cells) and obtained functional nerve cells from them.
An international team of scientists led by a Cold Spring Harbor Laboratory (CSHL) investigator has discovered that the deadly facial tumors decimating Australia's Tasmanian devil population probably originated in Schwann cells, a type of tissue that cushions and protects nerve fibers.
A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Medication poisonings among children are an important public health problem. During 2010-2011, an average of 1500 children under 6 years of age was evaluated in emergency departments each year due to unintentional exposure to buprenorphine. Ingestion of strong opioids, such as buprenorphine, can cause central nervous system depression, respiratory depression, and death in young children.
› Verified 9 days ago
Mohamed Ashkar, Pediatrics Medicare: Medicare Enrolled Practice Location: 1510 Florida Ave, Modesto, CA 95350 Phone: 209-722-4842 | |
Angela I Lin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1144 Coffee Rd, Modesto, CA 95355 Phone: 209-550-4744 | |
Miss Donna Silva, NP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4120 Prescott Rd, Modesto, CA 95356 Phone: 209-544-7300 Fax: 209-544-7323 | |
Dr. Mary Jessie Sumithra, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 4125 Bangs Ave, Modesto, CA 95356 Phone: 209-557-1630 | |
Dena Ann Lenser, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3109 Coffee Rd, Ste A, Modesto, CA 95355 Phone: 209-522-0001 Fax: 209-549-7077 | |
Rabia Formoli, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-557-1000 |